Clinical Trial Detail

NCT ID NCT03816332
Title Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

basal cell carcinoma

skin squamous cell carcinoma

Merkel cell carcinoma

Advanced Solid Tumor

melanoma

Therapies

Ipilimumab + Nivolumab + Prednisone + Tacrolimus

Age Groups: adult senior

No variant requirements are available.